



(12) Translation of
European patent specification

(11) NO/EP 3555097 B1

NORWAY

(19) NO

(51) Int Cl.

C07D 471/14 (2006.01)

A61K 31/437 (2006.01)

A61P 29/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.08.29
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.06.15
(86)	European Application Nr.	17854175.1
(86)	European Filing Date	2017.12.15
(87)	The European Application's Publication Date	2019.10.23
(30)	Priority	2016.12.16, US, 201662435609 P 2017.11.30, US, 201762592680 P 2017.12.08, US, 201762596607 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
	Designated Extension States:	BA; ME
	Designated Validation States:	MA; MD; TN
(73)	Proprietor	Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium
(72)	Inventor	KOUDRIAKOVA, Tatiana, 3210 Merryfield Row, San Diego, California 92121, USA KREUTTER, Kevin D., 1400 McKean Road, Spring House, Pennsylvania 19477, USA LEONARD, Kristi, Welsh and McKean Roads, Spring House, Pennsylvania 19477, USA RIZZOLIO, Michele C., 3210 Merryfield Row, San Diego, California 92121, USA SMITH, Russell C., 3210 Merryfield Row, San Diego, California 92121, USA TICHENOR, Mark S., 3210 Merryfield Row, San Diego, California 92121, USA WANG, Aihua, Welsh and McKean Roads, Spring House, Pennsylvania 19477, USA
(74)	Agent or Attorney	AWA NORWAY AS, Hoffsvæien 1A, 0275 OSLO, Norge

(54)	Title	IMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDINE COMPOUNDS AS INHIBITORS OF JANUS KINASES
(56)	References Cited:	WO-A1-2011/086053 WO-A1-2013/007765 MARK ZAK ET AL: "Identification of C -2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 11, 31 May 2013 (2013-05-31), pages 4764-4785, XP055462006, ISSN: 0022-2623, DOI: 10.1021/jm4004895

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse valgt fra gruppen bestående av

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-N-(2-hydroksy-2-metylpropyl)-
5 acetamid;

2-((1*r*,4*r*)-4-(2-(1*H*-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo[2,3-*b*]-
pyridin-1(6*H*)-yl)cykloheksyl)acetonitril;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-N-(cyklopropylmetyl)-
10 acetamid;

N-(2-Cyanoetyl)-2-(1-((1*r*,4*r*)-4-(cyanometyl)cykloheksyl)-1,6-
dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-N-(tetrahydro-2*H*-pyran-4-
15 yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-N-((tetrahydro-2*H*-pyran-4-
yl)metyl)acetamid;

N-(2-Cyano-2-metylpropyl)-2-(1-((1*r*,4*r*)-4-(cyanometyl)-
20 cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-
yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-N-((1-hydroksycyklobutyl)-
metyl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(1-metyl-1*H*-pyrazol-4-yl)-
acetamid;

N-(4-(Cyanometyl)bicyklo[2.2.1]heptan-1-yl)-2-(1-((1*r*,4*r*)-4-
5 (cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo-
[2,3-*b*]pyridin-2-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(1*H*-pyrazol-3-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
10 [4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklopropyl)-
metyl)acetamid; og

farmasøytisk akseptable salter, og kombinasjoner derav.

2. Forbindelse ifølge krav 1, hvor forbindelsen er valgt fra
gruppen bestående av

15 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-hydroksy-2-
metylpropyl)acetamid;

2-((1*r*,4*r*)-4-(2-(1*H*-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo[2,3-*b*]-
pyridin-1(6*H*)-yl)cykloheksyl)acetonitril;

20 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(cyklopropylmetyl)-
acetamid;

N-(2-Cyanoetyl)-2-(1-((1*r*,4*r*)-4-(cyanometyl)cykloheksyl)-1,6-
dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(tetrahydro-2H-pyran-4-
yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
5 [4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklobutyl)-
metyl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklopropyl)-
metyl)acetamid; og

10 farmasøytisk akseptable salter, og kombinasjoner derav.

3. Forbindelse ifølge krav 1, hvor forbindelsen er valgt fra
gruppen bestående av

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-hydroksy-2-
15 metylpropyl)acetamid;

2-((1*r*,4*r*)-4-(2-(1H-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo[2,3-*b*]-
pyridin-1(6H)-yl)cykloheksyl)acetonitril;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(cyklopropylmetyl)-
20 acetamid;

N-(2-Cyanoetyl)-2-(1-((1*r*,4*r*)-4-(cyanometyl)cykloheksyl)-1,6-
dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(tetrahydro-2H-pyran-4-yl)acetamid; og

farmasøytisk akseptable salter, og kombinasjoner derav.

- 5 4. Forbindelse ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående av

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-hydroksy-2-metylpropyl)acetamid;

- 10 2-((1*r*,4*r*)-4-(2-(1*H*-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo-[2,3-*b*]pyridin-1(6*H*)-yl)cykloheksyl)acetonitril;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklobutyl)-metyl)acetamid og

- 15 farmasøytisk akseptable salter, og kombinasjoner derav,

valgfritt hvor forbindelsen er:

(a) 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-hydroksy-2-metylpropyl)acetamido; eller

- 20 (b) 2-((1*r*,4*r*)-4-(2-(1*H*-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo-[2,3-*b*]pyridin-1(6*H*)-yl)cykloheksyl)acetonitril; eller

(c) 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklobutyl)metyl)acetamid.

5 5. Forbindelse ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående av

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((tetrahydro-2*H*-pyran-4-yl)metyl)acetamid;

10 *N*-(2-Cyano-2-metylpropyl)-2-(1-((1*r*,4*r*)-4-(cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklobutyl)metyl)acetamid;

15 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(1-metyl-1*H*-pyrazol-4-yl)acetamid;

20 *N*-(4-(Cyanometyl)bicyklo[2.2.1]heptan-1-yl)-2-(1-((1*r*,4*r*)-4-(cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(1*H*-pyrazol-3-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklopropyl)-metyl)acetamid; og

farmasøytisk akseptable salter, og kombinasjoner derav.

- 5 6. Forbindelse ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående av

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-hydroksy-2-metylpropyl)acetamid;

- 10 2-((1*r*,4*r*)-4-(2-(1*H*-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-1(6*H*)-yl)cykloheksyl)acetonitril;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(cyklopropylmetyl)-acetamid;

- 15 *N*-(2-Cyanoetyl)-2-(1-((1*r*,4*r*)-4-(cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(tetrahydro-2*H*-pyran-4-yl)acetamid;

- 20 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklobutyl)-metyl)acetamid; og

farmasøytisk akseptable salter, og kombinasjoner derav.

7. Forbindelse ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående av

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((tetrahydro-2*H*-pyran-4-
5 yl)metyl)acetamid;

N-(2-Cyano-2-metylpropyl)-2-(1-((1*r*,4*r*)-4-(cyanometyl)-
cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-
yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
10 [4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklobutyl)-
metyl)acetamid; og

farmasøytisk akseptable salter, og kombinasjoner derav.

8. Forbindelse ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående av

15 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-hydroksy-2-
metylpropyl)acetamid;

N-(4-(Cyanometyl)bicyklo[2.2.1]heptan-1-yl)-2-(1-((1*r*,4*r*)-4-
(cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo-
20 [2,3-*b*]pyridin-2-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(1*H*-pyrazol-3-yl)acetamid;
og

farmasøytisk akseptable salter, og kombinasjoner derav.

9. Forbindelse ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående av

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-hydroksy-2-
5 metylpropyl)acetamid;

2-((1*r*,4*r*)-4-(2-(1*H*-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo[2,3-*b*]-
pyridin-1(6*H*)-yl)cykloheksyl)acetonitril;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklopropyl)-
10 metyl)acetamid; og

farmasøytisk akseptable salter, og kombinasjoner derav, valgfritt
hvor forbindelsen er valgt fra:

(a) gruppen bestående av

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
15 [4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-hydroksy-2-
metylpropyl)acetamid;

2-((1*r*,4*r*)-4-(2-(1*H*-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo[2,3-*b*]-
pyridin-1(6*H*)-yl)cykloheksyl)acetonitril; og

farmasøytisk akseptable salter, og kombinasjoner derav; eller

20 (b) gruppen bestående av

2-((1*r*,4*r*)-4-(2-(1*H*-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo[2,3-*b*]-
pyridin-1(6*H*)-yl)cykloheksyl)acetonitril;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklopropyl)-metyl)acetamid; og

farmasøytisk akseptable salter, og kombinasjoner derav; eller

- 5 (c) gruppen bestående av

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-hydroksy-2-metylpropyl)acetamid;

- 10 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklopropyl)-metyl)acetamid; og

farmasøytisk akseptable salter, og kombinasjoner derav.

10. Forbindelse ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående av

- 15 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-hydroksy-2-metylpropyl)acetamid;

2-((1*r*,4*r*)-4-(2-(1*H*-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-1(6*H*)-yl)cykloheksyl)acetonitril;

- 20 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(cyklopropylmetyl)-acetamid;

N-(2-Cyanoethyl)-2-(1-((1*r*,4*r*)-4-(cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(tetrahydro-2*H*-pyran-4-
5 yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((tetrahydro-2*H*-pyran-4-
yl)metyl)acetamid;

N-(2-Cyano-2-metylpropyl)-2-(1-((1*r*,4*r*)-4-(cyanometyl)-
10 cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-
yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklobutyl)-
metyl)acetamid;

15 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(1-metyl-1*H*-pyrazol-4-yl)-
acetamid;

N-(4-(Cyanometyl)bicyklo[2.2.1]heptan-1-yl)-2-(1-((1*r*,4*r*)-4-
(cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo-
20 [2,3-*b*]pyridin-2-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(1*H*-pyrazol-3-yl)acetamid;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklopropyl)-
25 metyl)acetamid; og

farmasøytisk akseptable kokrystaller derav.

11. Forbindelse ifølge krav 10, valgt fra gruppen bestående av

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-hydroksy-2-
5 metylpropyl)acetamid;

2-((1*r*,4*r*)-4-(2-(1*H*-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo[2,3-*b*]-
pyridin-1(6*H*)-yl)cykloheksyl)acetonitril;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklopropyl)-
10 metyl)acetamid; og

farmasøytisk akseptable kokrystaller derav.

12. Farmasøytisk sammensetning omfattende en terapeutisk
virkosom mengde av minst én forbindelse ifølge krav 1.

13. Farmasøytisk sammensetning ifølge krav 12, hvor
15 forbindelsen er valgt fra gruppen bestående av

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-hydroksy-2-
metylpropyl)acetamid;

2-((1*r*,4*r*)-4-(2-(1*H*-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo[2,3-*b*]-
20 pyridin-1(6*H*)-yl)cykloheksyl)acetonitril;

2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo-
[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-hydroksycyklopropyl)-
metyl)acetamid; og

farmasøytisk akseptable salter, og kombinasjoner derav, valgfritt hvor forbindelsen er:

- (a) 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-(2-
5 hydroksy-2-metylpropyl)acetamid; eller
- (b) 2-((1*r*,4*r*)-4-(2-(1*H*-Imidazol-4-yl)imidazo[4,5-*d*]pyrrolo-
[2,3-*b*]pyridin-1(6*H*)-yl)cykloheksyl)acetonitril; eller
- (c) 2-(1-((1*r*,4*r*)-4-(Cyanometyl)cykloheksyl)-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl)-*N*-((1-
10 hydroksycyklopropyl)metyl)acetamid.